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Aluminum (Al)-based salts are widely used adjuvants in ruminants and other species strengthening 22 
the immune response elicited against vaccine antigen/s. However, they can lead to the formation of 23 
long-lasting granulomas composed of abundant activated macrophages. Small ruminant lentiviruses 24 
(SRLV) are widely distributed macrophage-tropic retroviruses that cause persistent infections in 25 
sheep and goats. Infected monocytes/macrophages and dendritic cells establish an inflammatory 26 
microenvironment that eventually leads to clinical manifestations. The aim of this work was to study 27 
the effect of Al-induced granulomas in the replication and pathogenesis of SRLV. Eleven adult, 28 
naturally SRLV-infected sheep showing clinical arthritis were distributed in Vaccine (n=6), 29 
Adjuvant-only (n=3) and Control (n=2) groups and inoculated with commercial Al-based vaccines, 30 
Al hydroxide adjuvant or phosphate buffered saline, respectively. In vitro studies demonstrated viral 31 
replication in Al-induced granulomas in 5 out of 10 sheep. Immunohistochemistry (IHC) evinced 32 
granular, intracytoplasmic SRLV presence in macrophages within granulomas. Viral sequences 33 
obtained from granulomas, blood monocytes and other tissues were highly similar in most animals, 34 
suggesting virus circulation among body compartments. However, notable differences between 35 
isolated strains in granulomas and other tissues in specific animals were also noted. Interestingly, the 36 
B2 subtype was the most commonly found SRLV genotype reaching a wider body distribution than 37 
previously described. Recombination events between genotypes B2 and A3 along gag region were 38 
identified in two sheep. Our results indicate that Al-hydroxide derived granulomas may represent an 39 
ideal compartment for SRLV replication, perhaps altering natural SRLV infection by providing a 40 

































Importance  44 
Granulomas are inflammation-derived structures elicited by foreign bodies or certain infections. 45 
Aluminum adjuvants included in vaccines induce granulomas in many species. In sheep, these are 46 
persistent and consist of activated macrophages. Small Ruminant Lentiviruses (SRLV), which are 47 
macrophage-tropic lentivirus, cause a chronic wasting disease affecting animal welfare and 48 
production. Here, we studied the occurrence of SRLV in post-vaccination granulomas retrieved from 49 
naturally infected ewes after vaccination or inoculation with aluminum only. SRLV infection was 50 
confirmed in granulomas by identification of viral proteins, genomic fragments and enzymatic 51 
activity. The infecting SRLV strain, previously found exclusively in carpal joints, reached the central 52 
nervous system, suggesting that occurrence of SRLV in post-vaccination granulomas may broaden 53 
tissue tropism. SRLV recombination was found in inoculated animals, a rare event in sheep 54 
lentiviruses. Potentially, virus-host interactions within granulomas may modify viral pathogenesis 55 

































Vaccines play a major role in controlling infectious diseases in animals and humans (1). Most 59 
vaccines are based on inactivated pathogens or recombinant proteins that are often poorly 60 
immunogenic. As a consequence, adjuvants are needed to strengthen the immune response against 61 
vaccine antigens (2, 3). Adjuvants in vaccines intended for veterinary use are mainly based on 62 
aluminum (Al) compounds and formulated as different salts, mostly Al hydroxide (4). Al content in 63 
vaccines and several other factors such as individual genetic background, number of inoculations, 64 
and antigen immunogenicity may raise undesired side effects including local inflammation or fever 65 
(5). In  sheep, post-injection inflammation leading  to granuloma formation, is a constant response 66 
after the inoculation of Al adjuvant (6). These granulomas consist of Al-loaded activated 67 
macrophages and multinucleated giant cells (6) and they have been described in almost all species 68 
including mice (7), pigs (8), cows (9), non-human primates (10) and humans (11, 12). 69 
Small ruminant lentiviruses (SRLV) are macrophage-tropic retroviruses that cause highly prevalent 70 
chronic infections in sheep and goats, linked to important detrimental effects on animal production 71 
and breeding stocks trade restrictions (13). SRLV have a defined tropism for the mononuclear-72 
phagocytic system altering cytokine production, MHC-II expression, and maturation state, thus 73 
leading to persistent inflammation. Infection is highly restricted in monocytes and classically 74 
activated M1-macrophages, but it is productive in M2-like and tissue differentiated macrophages (14, 75 
15). SRLV systemically disseminate and mostly affect, in an immune-mediated manner, lungs, brain, 76 
mammary gland and joints (16). Four main genotypes (A, B, C and E) and more than 35 subgroups 77 
with significant antigenic heterogeneity have been already characterized (17). In the articular form, 78 
the main clinical sign is unilateral or bilateral carpal arthritis and in sheep it is mainly caused by 79 
genotype B2 strains (18, 19). On the other hand, genotype A strains have been associated with 80 
outbreaks of encephalitis (20, 21), and is also related to pneumonia and mastitis. Recombination 81 
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between the most widely distributed SRLV genotypes A and B has been reported in goats from Italy 82 
(22), Canada (23) and Mexico (24) and only a single description of lentiviral recombination has been 83 
reported in sheep (25). Coinfection and recombination are hallmarks of lentivirus infections and may 84 
potentially expand their host-range species and promote colonization of different organs (26). After 85 
infection through respiratory secretions or colostrum intake, monocytes carrying the integrated 86 
provirus may distribute and differentiate into tissue macrophages triggering viral replication and 87 
inflammation, contributing to lesion development in target organs (16). 88 
Macrophages in granulomas might represent a replication site for SRLV that could modify viral 89 
pathogenesis by altering virus replication and immunological host responses. The aim of this work 90 
was to study the potential SRLV presence, replication and recombination in Al-induced granulomas 91 
ofnaturally infected sheep. 92 
Material and Methods  93 
Animals and experimental design 94 
Experimental design and procedures were licensed by the Ethical Committee of the University of 95 
Zaragoza (PI15/14). Requirements of the Spanish Policy for Animal Protection (RED53/2013) and 96 
the European Union Directive 2010/63 on the protection of experimental animals were always 97 
fulfilled. 98 
Nine adult (>4 year-old) Rasa Aragonesa ewes at the same production stage naturally infected by 99 
SRLV and showing lentivirus-induced bilateral arthritis in carpal joints were selected from three 100 
different flocks of Aragón (Spain). No other selection criteria were included at this stage. Upon 101 
checking for bacterial growth, only one animal showed Chlamydia spp. growth in joints, and it was 102 
disregarded for this study. Sheep were lodged at the experimental farm of the University of Zaragoza, 103 
and kept for 75 days under appropriate housing, management and diet conditions. Animals were 104 
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divided into 3 groups and injected with different substances: Vaccine group (n=4; animals V-1, V-2, 105 
V-3 and V-4) was inoculated with commercial vaccines, Adjuvant-only group (n=3; animals A-5, A-106 
6, and A-7) received Al hydroxide (Alhydrogel®, CZ Veterinaria) and Control group (n=2; animals 107 
C-8 and C-9) was injected with PBS. Vaccination record of these animals prior to the study was 108 
unknown.  109 
The vaccine inoculation protocol during the experiment followed manufacturer’s instructions, i.e., 110 
prime vaccination and boosting at 21-30 days. After the recommended resting period, a second round 111 
of vaccination was applied following the same protocol. Commercial vaccines, antigens, inoculations 112 
days and Al dosage are detailed in Figure 1. Animals received 8 subcutaneous inoculations 113 
distributed in 4 injection dates, i.e., two vaccines were applied at each date, one at each thoracic 114 
flank, with 21-days intervals between them. The four injections at each side were symmetrically 115 
distributed forming a square in the subcutaneous thoracic tissue. Euthanasia was carried out at 75 116 
days post first inoculation (dpi). Al content of each inoculum was measured by inductively coupled 117 
plasma mass spectrometry. Vaccine and Adjuvant-only groups received a total of 43.36 mg of Al per 118 
animal. Al content in PBS was always below the detection limit of the technique (0.074 µg/mL). A 119 
further Vaccine-Extra group (n=2; animals V-10 and V-11) of the same breed and age was 120 
established after the end of this first experiment to confirm and complement the molecular results 121 
obtained. These two sheep were housed under the same conditions and subjected to the same 122 
injection protocol until euthanasia at 40 dpi, therefore receiving four inoculations in total. 123 
In vivo studies 124 
General clinical examination and blood sampling were performed at 0, 40 and 75 dpi.  Peripheral 125 
blood mononuclear cells (PBMCs) were isolated on a Ficoll-Hypaque gradient (δ=1.077; 126 
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Lymphoprep Axis-Shield) for DNA extraction from 6 mL EDTA tubes (BD Vacutainer®), and 2 mL 127 
of plasma were stored at -20ºC for antibody analysis using ELISA. 128 
Pathology  129 
Tissues were fixed in 10% neutral-buffered formalin for 48-72h. Additionally, selected samples from 130 
post-vaccination granulomas were fixed in a Zinc solution for 36h to carry out 131 
immunohistochemistry (IHC) against SRLV capsid antigen (27). 132 
Samples were routinely processed for paraffin embedding and 4 µm sections were stained with either 133 
standard hematoxylin-eosin (HE), lumogallion or IHC. Lumogallion is a specific staining for Al that 134 
was carried out only in granulomas, following a previously-described protocol (6, 28). For IHC, 135 
samples were subjected to pre-treatment for antigen retrieval (30 minutes in a solution of 10mM 136 
citric acid pH 6 immersed in a water bath at 95ºC), endogenous peroxidase inhibition and non-137 
specific binding sites blockade (20 minutes in normal horse serum diluted 1:200 in PBS). Tissue 138 
samples were then incubated overnight at 4ºC with a specific monoclonal antibody against p28 139 
capsid protein of SRLV (CAEP5A1, VMRD, USA), labelled for 30 minutes at room temperature 140 
with anti-mouse EnVision HRP System (DAKO, Agilent Technologies) and revealed with 3-3’-141 
diaminobenzidine. The specificity of the technique was controlled by immunolabelling granulomas 142 
from SRLV-free animals, obtained from previous studies (6). 143 
Serological tests 144 
Blood plasma was used for SRLV antibody screening using two commercially available ELISA kits: 145 
Elitest-MVV (Hyphen-Biomed, France), based on p25 recombinant protein and a transmembrane 146 
synthetic peptide both derived from genotype A (29); and Eradikit™ SRLV Screening kit (IN3 147 
diagnostic, Italy), based on a mixture of Gag and Env antigens belonging to three different SRLV 148 
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viral genotypes (30). Both assays were performed to confirm infection status at the beginning and the 149 
end of the experiment. 150 
Virus isolation  151 
For the in vitro studies, i) one granuloma per animal of the Vaccine and Adjuvant-only groups, ii) a 152 
single granuloma found in control sheep C-8, and iii) the four granulomas found in each animal of 153 
the Vaccine-Extra group were collected at necropsy. Therefore, a total of 16 granulomas were 154 
analyzed. Granulomas and tissue samples from carpal joints, spleen, mediastinal lymph node, brain 155 
and bronchoalveolar lavage (BAL) were kept in PBS with antibiotic/antimycotic mix solution 156 
(Sigma) and either processed immediately or stored in RNAlater (ThermoFisher) at -80ºC until used. 157 
Samples kept in PBS were cut in small pieces (1cm3) with a scalpel blade and seeded on 25cm2 flasks 158 
with Roswell Park Memorial Institute (RPMI) complete medium, supplemented with 1% of L-159 
glutamine, 1% of vitamins, 1% antibiotics/antimycotics mix, 1% non-essential amino acids, 10 mM 160 
sodium pyruvate, 50 µM β-mercaptoethanol and 10% fetal bovine serum (FBS). Cultures were 161 
maintained at 37°C in a humidified atmosphere containing 5% CO2 and medium was partially 162 
replaced every 3–7 days. Once per week, medium was collected and reverse transcriptase (RT) 163 
activity was determined using SYBR Green-based PCR-enhanced reverse transcriptase assays (SG-164 
PERT) (31). The presence of cytopathic effect was observed under light microscopy at each culture 165 
passage. 166 
Genetic characterization 167 
Genomic DNA from samples was extracted, using E.Z.N.A Blood DNA Mini Kit (Omega bio-tek) 168 
from the following sources: i) PBMCs; ii) trypsinized cultured cells from tissue cultures with positive 169 
RT activity; iii) tissue samples kept in RNAlater previously homogenized in a Micro-Dismembrator 170 
U (Sartorius) using steel beads. 171 
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SRLV viral DNA detection was carried out by partial amplification of LTR, gag and pol using PCR 172 
with primers and conditions previously described and detailed in Table 1 (32–37). Following PCR, 173 
classical amplicons were visualized in 1% agarose gels, purified, and cloned into pGEMT-easy® 174 
(Promega) or pJET1.2 blunt vector (ThermoFisher) according to the manufacturer’s instructions. 175 
Three positive clones were submitted to external Sanger sequencing (Stab Vida). Sequence analysis 176 
was carried out by comparison with GenBank deposited sequences using BioEdit, Chromas and 177 
SnapGene softwares. Phylogenetic trees were created using the web application (www.phylogeny.fr) 178 
and modified using MEGA version 10.0.5 software.  179 
SimPlot v.3.5.1 software was used to define genomic regions that display significant percentages of 180 
nucleotide sequence identity and provide indications of possible recombination events. Sequences 181 
obtained in this study were compared with reference sequences from all described SRLV genotypes. 182 
Results 183 
SRLV presence in animals 184 
Clinical examination and cell blood count revealed no significant differences between the treatment 185 
groups during the inoculation scheme (Kruskal Wallis; p>0.05). Infection by SRLV was confirmed in 186 
all the animals by both ELISA tests used and reactivity remained positive until the end of the 187 
experiment. PCR performed on DNA from PBMCs was less sensitive as a diagnostic tool compared 188 
to ELISA tests and identified 5 out of 11 and 6 out of 9 infected animals, at the beginning and the end 189 
of the experiment, respectively (Table 2).  190 
Granulomas in animal groups and SRLV presence 191 
At necropsy, 31 subcutaneous granulomas were recovered in the Vaccine group out of 32 vaccine 192 
injections (96.7%). In the Adjuvant–only group 19 granulomas were isolated out of 24 inoculations 193 
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(79.2%). Interestingly, one of the Control animals (C-8) exhibited a single low-sized granuloma, 194 
possibly associated with a prior on-farm vaccination. Histologically, granulomas were composed of 195 
abundant epithelioid macrophages and occasional multinucleated giant cells admixed with moderate 196 
numbers of lymphocytes, plasma cells and fibroblasts immersed in abundant collagenous matrix 197 
(Figure 2A). These granulomas inconstantly showed a central necrotic core. Lumogallion staining 198 
revealed abundant intracytoplasmic Al-positive deposits within epithelioid macrophages and giant 199 
cells in all evaluated granulomas (Figure 2B). Presence of SRLV in post-vaccination granulomas was 200 
assessed by IHC. Granular, intracytoplasmic positive immunolabelling was found in macrophages 201 
and multinucleated giant cells, whereas no labelling was observed in fibrous capsule, lymphocytes, 202 
and plasma cells (Figure 2C and 2D). Granulomas from SRLV negative animals consistently showed 203 
no staining. 204 
Virus isolation from tissue samples 205 
A total of 16 granulomas were submitted for tissue culture and monitored for cytopathic effect and 206 
RT activity for more than three weeks. Granulomas from sheep V-2, V-3, C-8, three out of four 207 
granulomas from V-10, and two out of four granulomas from V-11 showed cytopathic effect with the 208 
presence of syncytia and/or positive RT supernatants, thus indicating active SRLV replication in 5 209 
out of 10 sheep (Table 2). In spleen or BAL, 6 out of 9 samples showed active SRLV replication 210 
evidenced by the appearance of cytopathic effect in tissue culture and RT activity determinations 211 
(Table 2).  212 
SRLV genetic characterization 213 
DNA from carpal joint, brain, spleen, mediastinal lymph node, BAL and granulomas was submitted 214 
to SRLV genetic characterization. Positive PCR reactions from samples were purified, cloned into 215 
shuttle plasmids and sequenced. Genetic regions partially covered by the PCRs (LTR, gag and pol) 216 
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allowed phylogenetic classification of the circulating viruses. PCRs covering the capsid and 217 
nucleocapsid clustered sequences from PBMCs mainly within B2 genotypes and, just in one animal 218 
(V-11) within A genotypes (Figure 3A). Sequences covering LTR, matrix and capsid depicted 219 
exactly the same clustering pattern (Figure 3B). The genotype A sequence obtained from sheep V-11 220 
showed values of about 85% similarity when compared with GenBank reference sequences but was 221 
not unequivocally assigned to any previously described subgroup (Table 3). 222 
DNA from granuloma cultures contained sequences from different SRLV genotypes. In general, 223 
genotypes present in granulomas resembled those in PBMCs. Capsid and nucleocapsid fragment 224 
allocated all the sequences from granulomas as genotype B2 (Figure 3A), while sequences spanning 225 
LTR and matrix protein clustered in genotypes B2 and A3 (Figure 3B). Genotype B2 was the most 226 
prevalent and actually, it was similar to the previously-described SRLV B2 strain 496 (19). However, 227 
genotype A identified in granulomas from animals V-11, A-6 and C-8 (Figure 3A and 3B) were 228 
hardly assigned to previously known subtypes, as they showed similarity values of almost 85% in 229 
gag and pol genes compared with the genotypes A1, A2 and A3 (Table 3). 230 
In spleen or BAL, sequences obtained reflected a similar classification compared with PBMCs and 231 
granuloma samples, with genotype B2 being present in almost all samples. Remarkably, sequences 232 
related to the carpal joint-tropic B2 genotype were also identified in the brain of four sheep (V-2, V-233 
10, V-11 and A-7). Additional genotypes included the unassigned genotype A in spleen from animal 234 
V-3 (Figure 4). Viral sequences from granulomas, PBMCs and other tissues where highly similar in 235 
animals V-2 and V-10, whereas, they showed notable differences between the isolated strains in 236 
animals V-11, A-6 and C-8 (Figures 3 and 4). 237 
Sequences were analyzed with Bootscan and identified recombination events between genotypes A3 238 
and B2 in spleen of sheep C-8 and in PBMCs of sheep A-6 along gag-pol (Figure 5A) and LTR-gag 239 
regions (Figure 5B), respectively.  240 
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This work describes the presence and replication of SRLV in Al-induced granulomas of SRLV 242 
naturally-infected sheep. The occurrence of lentiviruses in iatrogenic granulomas has never been 243 
described before, and the study of possible interactions reveals a novel research field. Sheep provides 244 
a unique model for understanding this interaction as granuloma formation is a constant feature after 245 
the injection of Al-containing vaccines in this species (6), and SRLV is one of the most widespread 246 
viral infections in sheep and goats (16). SRLV target macrophages that actively phagocytize Al 247 
adjuvants (6, 15). Therefore, SRLV and Al can merge in single animals depending on the SRLV 248 
prevalence and the intensity of vaccination programs. 249 
Vaccination protocols in sheep farms may remarkably vary between areas or countries depending on 250 
the health status and challenges, the farming system, and other environmental and management 251 
factors (38, 39). These protocols can be affected by the implementation of compulsory vaccinations 252 
against emerging diseases (38), such as the vaccination campaigns for Bluetongue in Spain (40) and 253 
other European countries (41) about a decade ago. In the present study, a typical vaccination 254 
protocol, using bluetongue virus vaccine was followed to simulate a real-world scenario. Vaccines 255 
against bluetongue virus have been associated with increased SRLV seroprevalence in Spanish sheep 256 
farms after the compulsory vaccination against the virus (M. Vila, personal communication). 257 
However, high SRLV seroconversion rates in the context of this particular vaccination program 258 
against bluetongue virus in France have been attributed to false positive ELISA results due to vaccine 259 
contamination (42).  260 
SRLV infection was confirmed in all animals enrolled in our study, including controls by detecting 261 
SRLV antibodies, indicating that infection had been naturally established prior to the experiment. 262 
Nearly one granuloma per injection was detected at post-mortem examination, indeed, 96.7% and 263 
79.2% of the expected granulomas were recovered in the Vaccine and Adjuvant-only groups, 264 
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respectively. A similar result was obtained in a previous study (6), in which higher numbers of 265 
granulomas were recovered in vaccinated animals compared with sheep injected with Al hydroxide 266 
only. Additionally, sheep C-8 (Control group) showed an Al-containing subcutaneous granuloma, 267 
likely as a result of previous vaccination, since these granulomas can persist for at least 15 months 268 
(6) and the present experiment was performed with SRLV-infected, commercial animals for 75 days 269 
only. Therefore, occurrence of granulomas from on-farm vaccinations cannot be totally excluded in 270 
animals from the Vaccine or Adjuvant groups. 271 
SRLV presence was demonstrated in granulomas by IHC, which showed viral proteins in the 272 
cytoplasm of epithelioid macrophages and multinucleated giant cells. The positive signal was 273 
observed within intracytoplasmic granules with a pattern very similar to that of Al-containing 274 
phagolysosomes (6). This might indicate that the vacuoles induced by Al phagocytosis provide a 275 
suitable environment for viral replication. Intracytoplasmic location and granular aspect of positive 276 
immunolabelled viral particles have already been described in macrophages of other ovine tissues 277 
(43, 44). Similarly, lentivirus replication within granulomas has been found in Mycobacterium 278 
tuberculosis infected macaques and humans (45, 46). 279 
Moreover, SRLV presence and replication was detected in cultured macrophages derived from post-280 
vaccination granulomas by PCR, RT-activity and analysis of cytopathic effect in 50% of the sheep (5 281 
out of 10) showing subcutaneous granulomas. SRLV most likely reached granulomas via infected 282 
circulating monocytes; it is well known that migration of blood monocytes following pro-283 
inflammatory cytokine gradients is the most common mechanism for macrophage accumulation in 284 
interstitial tissues (47). Indeed, Al-containing macrophages in post-vaccination granulomas in mice 285 
derive from circulating monocytes (48). Additionally, resident macrophages may proliferate and 286 
collaborate in granuloma formation, as demonstrated in alveolar macrophages infected with M. 287 
tuberculosis (49).  288 
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Sequences obtained from circulating PBMCs demonstrated that most of the SRLV amplified 289 
belonged to the genotype B2, a genotype strongly related to sheep lentiviral arthritis in the area of the 290 
study (18, 19). Sheep V-11 presented sequences similar to the genotype A with similarity values 291 
which approximates 85%, around the threshold limit to consider the occurrence of a novel subtype. 292 
However, further studies are needed to fully support a new SRLV subtype designation. Sheep V-11, 293 
A-6 and C-8 showed coexistence of different quasi-species in the granulomas, the PBMCs and other 294 
tissues of the same animal. This phenomenon, known as compartmentalization, can be the result of 295 
either genetic variations in a single viral strain along time, or co-infection of a certain individual with 296 
several viral strains (22, 50, 51). Most of the virus sequences obtained from granulomas were very 297 
similar to those obtained from PBMCs, which is compatible with the aforementioned migration of 298 
SRLV-infected circulating monocytes to granulomas. 299 
Interesting results were obtained in sheep V-11. In this animal, sequences of the matrix and capsid 300 
regions of SRLV isolated in the granuloma were similar to those isolated in PBMCs. However, when 301 
capsid and nucleocapsid regions were sequenced, the viral sequences of the granuloma differed from 302 
the sequences obtained in PBMCs and were similar to those isolated in spleen, carpal joint and brain. 303 
This fact might indicate viral recombination in the granuloma, which was also supported by the 304 
presence of recombinant strains in spleen of two further animals, A-6 and C-8. Recombination highly 305 
expands virus variability by mixing genetic fragments from different genotypes in double-infected 306 
cells. This may have important implications for diagnosis, tissue tropism, host range, generation of 307 
escape mutants and SRLV transmission (26, 52). Recombination between genotypes A and B has 308 
been occasionally described in goats and rarely in sheep (22–25). 309 
These findings suggest that Al-induced granulomas may represent a compartment for SRLV 310 
replication and also for cell-to-cell propagation, an evolutionary-conserved mechanism of SRLV to 311 
elude immune surveillance (15, 43). SRLV replicate in activated macrophages (15) and granulomas 312 
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are focal chronic inflammatory reactions mostly composed of activated macrophages. Al hydroxide 313 
injection induces a robust inflammation with recruitment of blood monocytes, some of them 314 
potentially infected by SRLV (6). Monocyte maturation into activated macrophages will lead to 315 
phagocytosis of Al micron-sized aggregates inducing granuloma formation (6, 48) but it would also 316 
trigger SRLV replication in infected animals (15). This phenomenon could, at least partially, explain 317 
the high SRLV seroprevalence rates observed in Spanish regions, in which nearly all flocks are 318 
infected (53), and the application of Al-containing vaccines is intensive (38). This hypothetical 319 
association could have deep implications in the sheep industry since increased seroprevalence due to 320 
vaccination may bias ongoing SRLV control programs and accreditation schemes, both based on 321 
serological identification, hindering breeding stocks trade. Reduced milk and lamb production are 322 
linked to SRLV infection (13) and, hence, SRLV replication in Al-derived granulomas might also 323 
have a role in clinicopathologic features as well as productive traits. However, further experimental 324 
studies are needed to better understand these findings. 325 
Additionally, Al-induced granulomas may play a role in SRLV dissemination and tissue tropism due 326 
to the translocation of macrophages. It has been demonstrated that Al-loaded macrophages can 327 
systemically biodistribute from the granulomas to other body locations (6, 48). Furthermore, Al 328 
increase has been detected in the central nervous system (CNS) of experimentally vaccinated mice 329 
and sheep (48, 54). The SRLV nervous form is usually caused by genotype A strains (20, 21), which 330 
is in contrast with the presence of B2 strains in the brain of four animals in the present study. In 331 
previous studies, in sheep of the same breed and at the same regions, natural and experimental 332 
infection with a similar B2 strain resulted in clinical affection of carpal joints without presence of this 333 
strain in the CNS (55). This may suggest that Al-induced granulomas could favor a wider SRLV 334 
tissue tropism since in addition, Al derived from granulomas has been found in the spinal cord of 335 
vaccinated sheep (54). SRLV in the spinal cord may be associated with a particular nervous form 336 
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characterized by myelitis as the sole lesion (56). Analogous interactions have been described between 337 
SIV and M. tuberculosis-derived granulomas in infected macaques. SIV induces clinical reactivation 338 
and disrupted immune responses against latent M. tuberculosis infection by replicating within 339 
tuberculous granulomas (45).  340 
Alternative vaccine formulations including biocompatible and biodegradable adjuvants such as 341 
microcrystalline tyrosine or calcium phosphate have shown promising results in terms of protection 342 
against bacterial pathogens (57, 58). The use of Al-free vaccines in sheep may reduce granuloma 343 
formation and accordingly the availability of macrophages for SRLV to infect, while ensuring high 344 
protection rates. Further studies are needed to find out whether eventual granulomas after vaccination 345 
with alternative vaccines have any effect on SRLV replication. 346 
In conclusion, our results indicate that, in naturally infected sheep, Al-injection site granulomas 347 
possibly promote viral replication, body distribution and recombination, therefore, potentially 348 
modifying viral tropism and immunological responses. Data presented in this work may open a new 349 
research field in which new alternative adjuvants should elicit a protective immune response, 350 
avoiding granuloma formation. Finally, it is important to ascertain whether the findings described in 351 
this study are exclusive to the SRLV infection in sheep, or rather can be observed in macrophage-352 
tropic infections of other species developing granulomas. In cats, persistent inflammation induced 353 
after vaccination may reactivate Feline Leukemia virus infection contributing to emergence of 354 
cutaneous lymphomas at injection sites (59). Mechanisms underlying these and likely other 355 
interactions, such as HIV and M. tuberculosis, may involve virus infection of macrophages within 356 
granulomas, and need to be uncovered in order to improve vaccines safety.  357 
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Figure Legends 551 
Figure 1. Inoculation schedule and vaccines used. (A) Inoculations were administered at 0, 21, 42, 552 
and 63 days post first inoculation (dpi). Animals were euthanized at 75 dpi. (B) Description of the 553 
vaccines used. Aluminum (Al) content was established by inductively coupled mass spectrometry 554 
and calculated per dose. 555 
Figure 2: Post-vaccination granuloma. (A) Abundant epithelioid macrophages and multinucleated 556 
giant cells (asterisk) intermingled with lymphocytes and plasma cells are surrounded by dense 557 
fibrous (arrow) tissue and neovessels (arrowhead). Hematoxylin-Eosin stain, 10x. (B) Multiple 558 
intense yellowish fluorescent aluminum (Al) deposits are located within the cytoplasm of 559 
macrophages and giant cells. Lumogallion stain, 40x.  (C) Positive immunolabelling against Gag 560 
proteins of Small ruminant lentiviruses (SRLV) of epithelioid macrophages (asterisk) within the 561 
granuloma. Note the negative result in the connective tissue (arrow), 10x. (D) Detail of positive 562 
macrophages by immunohistochemistry showing granular, intracytoplasmic labelling against SRLV, 563 
40x.  564 
Figure 3: Phylogenetic trees of SRLV sequences isolated from Vaccine (V), Adjuvant-only (A) and 565 
Control (C) sheep. (A) SRLV capsid and nucleocapsid sequences obtained from peripheral blood 566 
mononuclear cells (PBMCs). (B) SRLV LTR and matrix sequences in PBMCs.  567 
Figure 4: Phylogenetic tree of SRLV matrix sequences isolated from carpal joint, brain, spleen, 568 
mediastinal lymph node and bronchoalveolar lavage (BAL) obtained from Vaccine (V), Adjuvant-569 
only (A) and Control (C) sheep.  570 
Figure 5: Recombination analysis of gag-pol Small ruminant lentiviruses sequences from sheep C8 571 
spleen (A) and LTR-gag sequences from sheep A6 PBMCs (B). Recombinant sequences were first 572 
detected in RDP followed by Bootscan analysis of consensus sequences in Simplot using a window 573 
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size of 200, a step size of 20, 1000 replicates, gap striping and the Kimura 2 distance model with the 574 
NJ tree model. Breakpoints on the recombinant sequences are indicated by orange vertical lines. 575 
Recombination analysis revealed that recombinant SRLV sequences were the result of a 576 
































Table 1. Characteristics of primers used in this work for diagnosis and genetic characterization of 579 
Small ruminant lentiviruses DNA. 580 
 581 












OSLO GGCATCATGGCTAATACTTCTAA Rv (33) 






OSLO GGCATCATGGCTAATACTTCTAA Rv (33) 





CAEV R2 GGACGGCACCACACGTAKCCC Rv 





GAG F2 CAAACWGTRGCAATGCAGCATGG Fw 
POL R1 CATAGGRGGHGCGGACGGCASCA Rv 
POL R2 GCGGACGGCASCACACG Rv 






POLEV1NERV TCCCGAATTTGTTTCTACCC Rv This study 
































Table 2. Serological and PCR results from the Small ruminant lentiviruses naturally-infected sheep 583 
included in the study including presence of virus in granuloma, bronchoalveolar lavage (BAL) and 584 
spleen tissue cultures. Animals from the Vaccine (V), Adjuvant-only (A) and Control (C) groups 585 
were analyzed by commercial ELISA and diagnostic PCR targeting gag region. The PCR was 586 
performed on DNA isolated from PBMCs. Granuloma samples were cultured in vitro and analyzed 587 
for RT activity by SG-PERT. 588 
 589 
      ELISA   PCR   RT activity 
Group Animal 
 
0 dpi 40 dpi 75 dpi 
 
0 dpi 40 dpi 75 dpi 
 




+ + + 
 
- - - 
 
- + + 
V-2 
 
+ + + 
 
- - + 
 
+ + - 
V-3 
 
+ + + 
 
- - - 
 
+ + + 
V-4 
 
+ + + 
 
- - + 
 
- + - 
 V-10 
 
+ + ND 
 
+ + ND 
 
+ ND ND 
 V-11 
 
+ + ND 
 
+ + ND 
 





+ + + 
 
- - - 
 
- - + 
A-6 
 
+ + + 
 
+ - + 
 
- + + 
A-7 
 
+ + + 
 
- - + 
 
- + + 
Control C-8  
+ + + 
 
+ + + 
 
+ - + 
C-9   + + +   + - +   ND + - 
 
ND: Not determined 
         dpi: days post first inoculation 
        590 
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Table 3. Sequence identity matrix among sequences found in animals V-6, V-11 and C-8 and 591 
standard GenBank deposited sequences for Small ruminant lentiviruses from the indicated genotypes. 592 
Numbers in sequences represent the different clones analyzed. Values in bold highlight the most 593 
















V-11 PBMCs t0 gag 0.776 0.822 0.858 0.734 0.722 0.650 0.694 
V-11 PBMCs t0 ltr-gag 0.649 0.667 0.752 0.454 0.450 0.510 0.450 
V-11 Granuloma ltr-gag 0.707 0.718 0.815 0.502 0.488 0.554 0.494 
A-6 Granuloma gag 0.727 0.765 0.738 0.941 0.830 0.650 0.735 
A-6 Granuloma-1 ltr-gag 0.710 0.707 0.790 0.503 0.486 0.582 0.501 
A-6 Granuloma-2 ltr-gag 0.711 0.708 0.791 0.506 0.489 0.585 0.502 
A-6 Granuloma-3 ltr-gag 0.710 0.708 0.792 0.503 0.486 0.584 0.502 
C-8 Granuloma-1 gag-pol 0.809 0.826 0.847 0.758 0.753 0.721 0.731 
C-8 Granuloma-2 gag-pol 0.808 0.826 0.847 0.757 0.752 0.720 0.730 
C-8 Granuloma-1 ltr-gag 0.711 0.708 0.791 0.505 0.489 0.584 0.502 
C-8 Granuloma-2 ltr-gag 0.711 0.708 0.791 0.505 0.489 0.582 0.502 
C-8 Spleen-1 gag-pol 0.744 0.757 0.755 0.870 0.811 0.691 0.746 
C-8 Spleen-2 gag-pol 0.751 0.766 0.755 0.874 0.819 0.699 0.754 
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